Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
Applied DNA Sciences (NASDAQ:APDN) has announced the rescheduling of its Investor Update call from January 9, 2025, to Thursday, February 13, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Applied DNA Sciences (NASDAQ:APDN) has announced the rescheduling of its Investor Update call from January 9, 2025, to Thursday, February 13, 2025. The rescheduling aligns with the release of the company's first quarter fiscal 2025 financial results. The original call was intended to provide shareholders with updates on the company's strategic restructuring announced in December 2024 and GMP initiative. The schedule change is due to the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.
Details
News Market Reaction – APDN
The recorded move for APDN in the trading session of this news was +0.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.
The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
For additional information:
Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: https://investors.adnas.com/
SOURCE: Applied DNA Sciences, Inc.
View the original press release on accesswire.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.